Product Center
Trivalent and quadrivalent influenza virus subunit vaccines (adjuvants) have entered phase I clinical trials as scheduled
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-13
- Views:
(Summary description)Recently, Jiangsu Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Yither Bio") jointly applied for the Phase I clinical trials of a new drug, "Influenza Virus Subunit Vaccine (Adjuvant)" and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", which have been successfully launched in Hubei. These two vaccine research and development achievements are steadily being realized as company performance, and also mark a solid step towards the goal of providing the most accurate coverage for different age groups and different demand groups in the company's sub unit influenza vaccine product pipeline.
Trivalent and quadrivalent influenza virus subunit vaccines (adjuvants) have entered phase I clinical trials as scheduled
(Summary description)Recently, Jiangsu Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Yither Bio") jointly applied for the Phase I clinical trials of a new drug, "Influenza Virus Subunit Vaccine (Adjuvant)" and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", which have been successfully launched in Hubei. These two vaccine research and development achievements are steadily being realized as company performance, and also mark a solid step towards the goal of providing the most accurate coverage for different age groups and different demand groups in the company's sub unit influenza vaccine product pipeline.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-13 09:02
- Views:
Recently, Jiangsu Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Yither Bio") jointly applied for the Phase I clinical trials of a new drug, "Influenza Virus Subunit Vaccine (Adjuvant)" and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", which have been successfully launched in Hubei. These two vaccine research and development achievements are steadily being realized as company performance, and also mark a solid step towards the goal of providing the most accurate coverage for different age groups and different demand groups in the company's sub unit influenza vaccine product pipeline.
At present, influenza virus remains one of the important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross species transmission and pandemics of influenza virus have significant impacts on human health and socio-economic development. Compared to other age groups, the elderly have a higher infection rate and a greater risk of severe illness and death after contracting the flu, which increases with age. WHO and the Chinese Center for Disease Control and Prevention recommend elderly people as one of the priority groups for influenza vaccination.
Adjuvant containing influenza virus subunit vaccine is a flu vaccine developed by the company in response to the vaccination needs of different populations and WHO's recommendations for flu vaccines. It is suitable for the elderly aged 65 and above, using the company's mature platform technology and new adjuvants. Preclinical studies have shown that influenza virus subunit vaccines containing adjuvants can significantly increase the body's antibody levels and neutralizing antibody titers, and have significant advantages in enhancing immune response capabilities, providing the optimal choice for elderly populations to cope with influenza.
Relevant information
-
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. - Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
